Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus.
about
Stem Cell-Based Cell Carrier for Targeted Oncolytic Virotherapy: Translational Opportunity and Open QuestionsAd5/48 hexon oncolytic virus expressing sTGFβRIIFc produces reduced hepatic and systemic toxicities and inhibits prostate cancer bone metastases.Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacyGlioma virus therapies between bench and bedside.
P2860
Switching a replication-defective adenoviral vector into a replication-competent, oncolytic adenovirus.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 23 October 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Switching a replication-defect ...... mpetent, oncolytic adenovirus.
@en
Switching a replication-defect ...... mpetent, oncolytic adenovirus.
@nl
type
label
Switching a replication-defect ...... mpetent, oncolytic adenovirus.
@en
Switching a replication-defect ...... mpetent, oncolytic adenovirus.
@nl
prefLabel
Switching a replication-defect ...... mpetent, oncolytic adenovirus.
@en
Switching a replication-defect ...... mpetent, oncolytic adenovirus.
@nl
P2860
P356
P1433
P1476
Switching a replication-defect ...... mpetent, oncolytic adenovirus.
@en
P2093
E Antonio Chiocca
Hiroshi Nakashima
P2860
P304
P356
10.1128/JVI.02668-13
P407
P577
2013-10-23T00:00:00Z